Navigation Links
Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
Date:10/27/2011

THE WOODLANDS, Texas, Oct. 27, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it will release its third quarter 2011 financial results on Tuesday, November 1, 2011 before the financial markets open.  Lexicon management will hold a conference call to discuss program status and financial results for the quarter at 11:00 a.m. Eastern Time that same day.

The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international).  The conference ID for all callers is 20122666.  Investors can access a live webcast of the call at www.lexpharma.com.  An archived version of the conference call will be available on Lexicon's corporate website through November 29, 2011.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
2. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
3. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
4. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
5. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
6. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
7. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
8. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
9. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
10. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
11. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ORANGE COUNTY, Calif. , May 27, 2016  A new study highlights the ... study conducted by the  Journal of the American College of Radiology , a majority ... particular procedures. Photo - http://photos.prnewswire.com/prnh/20160527/373022 ... ... Medical Diagnostic ...
(Date:5/27/2016)... , May 27, 2016 ... instances of hypertension is driving ambulatory blood pressure monitoring ... their elasticity and their ability to respond to different ... This condition can lead to various cardiovascular disorders such ... vascular disease. These diseases are growing in prevalence each ...
(Date:5/27/2016)... TEL-AVIV, Israel , May 27, 2016 /PRNewswire/ ... KTOV), an innovative biopharmaceutical company focused on late-stage ... by Dexcel Pharma of pivotal batches ... Food and Drug Administration (FDA). This follows Kitov,s ... pivotal Phase III trial successfully met its primary ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... ... According to recent statistics, there are nearly half a million physical ... Each physical therapy professional and every clinic has a duty to perform at the ... a competitive industry is also essential. The solution that many physical therapy leaders turn ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... FDAI, DAHC, CDC, has joined the Fire Door Solutions’ team. Keith will ... fire door and frame in-field re-labeling. He will be instrumental in developing ...
(Date:5/31/2016)... ... ... More than 80 representatives of the Hepatitis B Foundation , Hepatitis ... an event on National Hepatitis Testing Day outside of Philadelphia City Hall to raise ... of liver cancer. , Foundation leaders and the citywide coalition they created, Hep B ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... Healthconnect’s (Healthconnect) regional health information exchange, which enables physicians at SJMC’s two hospital ... patients from other participating organizations in the exchange. SJMC’s membership in the health ...
(Date:5/31/2016)... Beach, Florida (PRWEB) , ... May 31, 2016 ... ... to Jay Butch of CertainTeed Corporation, he knew it was something that contractors ... as state-of-the-art and cutting-edge as it gets,” says Butch, CertainTeed’s Director of Contractor ...
Breaking Medicine News(10 mins):